AgeX Therapeutics AGE Stock
AgeX Therapeutics Price Chart
AgeX Therapeutics AGE Financial and Trading Overview
| AgeX Therapeutics stock price | 11.1 USD |
| Previous Close | 0.65 USD |
| Open | 0.66 USD |
| Bid | 0 USD x 1000 |
| Ask | 0.7 USD x 1100 |
| Day's Range | 0.66 - 0.68 USD |
| 52 Week Range | 0.37 - 0.84 USD |
| Volume | 7.29K USD |
| Avg. Volume | 20.78K USD |
| Market Cap | 25.96M USD |
| Beta (5Y Monthly) | 1.506295 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | 0 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
AGE Valuation Measures
| Enterprise Value | 55.62M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 665.6074 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 1426.171 |
| Enterprise Value/EBITDA | -8.004 |
Trading Information
AgeX Therapeutics Stock Price History
| Beta (5Y Monthly) | 1.506295 |
| 52-Week Change | 10.32% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.84 USD |
| 52 Week Low | 0.37 USD |
| 50-Day Moving Average | 0.58 USD |
| 200-Day Moving Average | 0.61 USD |
AGE Share Statistics
| Avg. Volume (3 month) | 20.78K USD |
| Avg. Daily Volume (10-Days) | 16.27K USD |
| Shares Outstanding | 37.95M |
| Float | 18.46M |
| Short Ratio | 7.71 |
| % Held by Insiders | 43.46% |
| % Held by Institutions | 12.62% |
| Shares Short | 231.14K |
| Short % of Float | 1.08% |
| Short % of Shares Outstanding | 0.61% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -18156.40% |
| Gross Margin | 66.66% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -58.052% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 39K USD |
| Revenue Per Share (ttm) | 0.001 USD |
| Quarterly Revenue Growth (yoy) | 100.00% |
| Gross Profit (ttm) | N/A |
| EBITDA | -6949000 USD |
| Net Income Avi to Common (ttm) | -11033000 USD |
| Diluted EPS (ttm) | -0.3 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 280K USD |
| Total Cash Per Share (mrq) | 0.007 USD |
| Total Debt (mrq) | 30.05M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.078 |
| Book Value Per Share (mrq) | -0.524 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -6168000 USD |
| Levered Free Cash Flow (ttm) | -3512625 USD |
Profile of AgeX Therapeutics
| Country | United States |
| State | CA |
| City | Alameda |
| Address | 1101 Marina Village Parkway |
| ZIP | 94501 |
| Phone | (510) 671-8370 |
| Website | https://www.agexinc.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 5 |
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease. Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.
Q&A For AgeX Therapeutics Stock
What is a current AGE stock price?
AgeX Therapeutics AGE stock price today per share is 11.1 USD.
How to purchase AgeX Therapeutics stock?
You can buy AGE shares on the NYSE American exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for AgeX Therapeutics?
The stock symbol or ticker of AgeX Therapeutics is AGE.
Which industry does the AgeX Therapeutics company belong to?
The AgeX Therapeutics industry is Biotechnology.
How many shares does AgeX Therapeutics have in circulation?
The max supply of AgeX Therapeutics shares is 2.5M.
What is AgeX Therapeutics Price to Earnings Ratio (PE Ratio)?
AgeX Therapeutics PE Ratio is 0.00000000 now.
What was AgeX Therapeutics earnings per share over the trailing 12 months (TTM)?
AgeX Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the AgeX Therapeutics company belong to?
The AgeX Therapeutics sector is Healthcare.